shRNA沉默增殖诱导配体基因抑制胰腺癌细胞生长的研究

目的 研究靶向增殖诱导配体(a proliferation-inducing ligand,APRIL)基因的短发夹RNA(short hairpin RNA,shRNA)在体内外对胰腺癌细胞生长的影响,探讨其对胰腺癌基因治疗的可行性.方法 将前期构建的LV-shAPRIL感染CFPAC1细胞,MTY法及流式细胞技术分别检测CFPAC1细胞生长和凋亡.用CFPAC1细胞建立裸鼠移植瘤模型,观察瘤内注射LV-shAPRIL对瘤生长的影响.结果 LV-shAPRIL感染CFPAC1细胞96 h后,CFPAC1细胞的生长明显受抑制,与对照组及空载体组相比有显著差异(P＜0.05);同时细胞凋亡率为(17.35±0.96)%,明显高于对照组和空载体组(P＜0.05).将LV-shAPRIL局部注射到裸鼠移植瘤内,LV-shAPRIL组肿瘤生长明显比同期对照组和空载体组减缓;第27天LV-shAPRIL组肿瘤体积和重量分别为(821.8±123.3)mm3和(2.16±0.18)g,明显小于其他两组(P＜0.05).结论 靶向APRIL基因的慢病毒表达载体LV-shAPRIL在体内外抑制胰腺癌CFPAC1细胞的生长,为胰腺癌基因治疗探索新的思路.

The inhibitive effect of the pancreatic cancer cells mediating by shRNA targeting APRIL gene

Objective To investigate the inhibitive effect of shRNA (short hairpin RNA) targeting APRIL gene on the pancreatic cancer cells in vitro and in vivo, in order to explore the feasibility of gene therapy for pancreatic cancer. Methods The LV-shAPRIL targeting APRIL gene had been constructed before, and was used to infect the CFPAC-1 cells. Cell proliferation and apoptosis were examined by MTT and flow cytometry. Then CFPAC-1 cells were used to construct the model of transplantation tumor into the nude mice, the tumor growth was assessed after LV-shAPRIL treatment. Results 96 hours after the LV-shAPRIL infection into CFPAC-1 cells, the cell proliferation was significantly inhibited when compared with control group and lentivirus infection group (P＜0.05 ). Flow cytometry showed the apoptosis ratio of the CFPAC-1 cells was (17.35±0.96)% in LV-shAPRIL group, which was higher than that in control group and lentivirus infection group (P＜0.05 ). After LV-shAPRIL injection into the model of nude mice, the tumor growth was slower than that in the two control groups. The tumor's volume of the LV-shAPRIL group was(821.8±123.3) mm3 and the mass was (2.16±0.18)g at 27 day, and were obviously depressed, when compared with two control groups (P±0.05). Conclusions LV-shAPRIL targeting APRIL gene can inhibit the growth of the CFPAC-1 cells in vitro and vivo. This may provide a new gene therapy approach for pancreatic cancer.